RE:RE:RE:RE:RE:RE:AGM There are a lot of ways to value a pharma company. They typically trade on average at a P/S of 6X.
The earnings model is based on royalities with transfer pricing on top of that. I don't know how transfer pricing works.
Once again, things look promising, yet the share price sits still. This story needs to get out, most of us have bought as much as we can or want.
clyfor13yrs wrote:
I agree that the next few months will be interesting. Will results leak out or more importantly will Insider's start buying if results are truly "fantastic".
I would argue that these upcoming results are finally something tangible for Insiders to start supporting the stock, if positive
If Gilles is somewhat right about the market (10% of $4B):
$400M Revenue first year (if Ceapro partners then say what 200-300M to Ceapro)
What is the market cap of a company that brings in $300M revenue?
Hell of alot!
Even the Negative Nancy's on this board have to have a bit of excitement for this.
That being said, criticism towards management on the other initiatives is fair in my opinion, those are no where near close to increasing shareholder value as they make it seem in press releases and presentations.